A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation

European Urology - Tập 69 - Trang 788-794 - 2016
Prasanna Sooriakumaran1,2, Jeffrey Karnes3, Christian Stief4, Bethan Copsey5, Francesco Montorsi6, Peter Hammerer7, Burkhard Beyer8, Marco Moschini3, Christian Gratzke4, Thomas Steuber9, Nazareno Suardi6, Alberto Briganti6, Lukas Manka7, Tommy Nyberg2, Susan J. Dutton5, Peter Wiklund2,10, Markus Graefen9
1Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
2Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
3Mayo Clinic Department of Urology, Rochester, USA
4Department of Urology, Ludwig Maximilian University of Munich, Munich, Germany
5Centre for Statistics in Medicine, University of Oxford, Oxford, UK
6Department of Urology, San Raffaele Hospital, Milan, Italy
7Department of Urology/Uro-oncology, Academic Hospital Braunschweig, Brunswick, Germany
8Martini Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
9Martini-Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
10Uro-clinic, St. Goran Hospital, Stockholm, Sweden

Tài liệu tham khảo

Center, 2012, International variation in prostate cancer incidence and mortality rates, Eur Urol, 61, 1079, 10.1016/j.eururo.2012.02.054 Yossepowitch, 2007, The natural history of noncastrate metastatic prostate cancer after radical prostatectomy, Eur Urol, 51, 940, 10.1016/j.eururo.2006.10.045 James, 2015, Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019), Eur Urol, 65, 1028, 10.1016/j.eururo.2014.09.032 Gratzke, 2014, Role of radical prostatectomy in clinically non-organ-confined prostate cancer, Curr Urol Rep, 15, 455, 10.1007/s11934-014-0455-9 Mickisch, 2001, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, Lancet, 358, 966, 10.1016/S0140-6736(01)06103-7 Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013 Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, J Clin Oncol, 20, 1248, 10.1200/JCO.20.5.1248 Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012 Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry, Eur Urol, 66, 602, 10.1016/j.eururo.2014.04.009 Sooriakumaran, 2014, Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes, BMJ, 348, g1502, 10.1136/bmj.g1502 Psaila, 2009, The metastatic niche: adapting the foreign soil, Nat Rev Cancer, 9, 285, 10.1038/nrc2621 Ceelen, 2014, Surgery, wound healing, and metastasis: recent insights and clinical implications, Crit Rev Oncol Hematol, 89, 16, 10.1016/j.critrevonc.2013.07.008 Hong, 2015, Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer, Nat Commun, 6, 6605, 10.1038/ncomms7605 Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 Chapin, 2014, Is treatment of the primary tumor in metastatic prostate cancer justified?, Eur Urol, 65, 1067, 10.1016/j.eururo.2013.12.011 Tewari, 2012, Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy, Eur Urol, 62, 1, 10.1016/j.eururo.2012.02.029 Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study, J Urol, 193, 832, 10.1016/j.juro.2014.09.089 Sweeney, 2014, Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial, J Clin Oncol, 32, LBA2, 10.1200/jco.2014.32.18_suppl.lba2 Gakis, 2014, The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature, Eur Urol, 66, 191, 10.1016/j.eururo.2013.05.033 Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002 Surcel, 2015, Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey, BJU Int, 115, 571, 10.1111/bju.12796 Musch, 2008, Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006, J Urol, 179, 923, 10.1016/j.juro.2007.10.072 Heidenreich, 2014, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013, Eur Urol, 65, 124, 10.1016/j.eururo.2013.09.046 Treiyer, 2011, A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy, J Urol, 185, 1681, 10.1016/j.juro.2010.12.052